Study of REM-422 in Patients With AML or Higher Risk MDS
Conditions: Myelodysplastic Syndromes; Higher Risk Myelodysplastic Syndromes; Acute Myeloid Leukemia; Acute Myeloid Leukemia Refractory Interventions: Drug: REM-422 Sponsors: Remix Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 7, 2024 Category: Research Source Type: clinical trials
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
Conditions: Hematologic Malignancies; Lymphoma; Multiple Myeloma; Leukemia; Blood Cancers Interventions: Behavioral: Preference Reporting to Improve Management and Experience (PRIME) Sponsors: UNC Lineberger Comprehensive Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 6, 2024 Category: Research Source Type: clinical trials
Personalized Medication Software for BCL-2 Inhibitor in AML Patients Using Machine Learning and Genomics
Conditions: Acute Myeloid Leukemia Sponsors: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 6, 2024 Category: Research Source Type: clinical trials
Raman Spectroscopy Compared to Flow Cytometry
Conditions: Acute Lymphoblastic Leukemia Interventions: Diagnostic Test: Raman spectroscopy Sponsors: Hospital Regional de Alta Especialidad del Bajio; Optics research center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 4, 2024 Category: Research Source Type: clinical trials
A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma Interventions: Drug: Obinutuzumab; Drug: ABBV-453 Sponsors: AbbVie Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 4, 2024 Category: Research Source Type: clinical trials
Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
Conditions: Acute Lymphoblastic Leukemia; Lymphoblastic Lymphoma; Mixed Phenotype Acute Leukemia Interventions: Drug: Dexamethasone; Drug: Vincristine; Drug: Daunorubicin; Drug: Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine); Drug: Methotrexate; Drug: Cytarabine Sponsors: St. Jude Children ' s Research Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 4, 2024 Category: Research Source Type: clinical trials
Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL
Conditions: DLBCL - Diffuse Large B Cell Lymphoma; High-grade B-cell Lymphoma; High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; DLBCL, Nos Genetic Subtypes; High Grade B-Cell Lymphoma, Not Otherwise Specified; Follicular Large Cell Lymphoma, Relapsed; Follicular Large Cell Lymphoma Interventions: Drug: Epcoritamab Sponsors: Australasian Leukaemia and Lymphoma Group Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 1, 2024 Category: Research Source Type: clinical trials
A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)
Conditions: Philadelphia-Negative ALL; Philadelphia-Positive ALL; Relapsed ALL, Adult; Refractory Acute Lymphoblastic Leukemia; Refractory Acute Lymphoblastic Leukemia (ALL); Refractory Acute Lymphoid Leukemia in Relapse Interventions: Biological: 19-28z/IL-18 CAR T cells Sponsors: Memorial Sloan Kettering Cancer Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 1, 2024 Category: Research Source Type: clinical trials
Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab
Conditions: Relapsed/Refractory; B-cell Acute Lymphocytic Leukemia Interventions: Drug: Blinatumomab; Drug: Inotuzumab Ozogamicin; Drug: Hyper-CVAD; Drug: Mini-hyper-CVD Sponsors: M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 1, 2024 Category: Research Source Type: clinical trials
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
Conditions: Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Myelodysplastic Syndrome Interventions: Biological: Actinium Ac 225-DOTA-Daratumumab; Procedure: Biospecimen Collection; Procedure: Bone Marrow Aspiration; Procedure: Bone Marrow Biopsy; Procedure: Computed Tomography; Biological: Daratumumab; Procedure: Echocardiography; Drug: Fludarabine; Procedure: Hematopoietic Cell Transplantation; Biological: Indium In 111-DOTA-Daratumumab; Drug: Melphalan; Procedure: Multigated Acquisition Scan; Procedure: Radionuclide Imaging; Procedure: Single Photon Emission Computed Tomography; Drug: Sirolimus; Drug: Tacrolimus; R...
Source: ClinicalTrials.gov - March 1, 2024 Category: Research Source Type: clinical trials
Safety and Efficacy of Venetoclax Combination With Decitabine(DEC3-VEN) in the Treatment of AML in the Adult
Conditions: Acute Myeloid Leukemia, Adult Interventions: Procedure: DEC3-VEN Sponsors: The Second Affiliated Hospital of Kunming Medical University; Institute of hematology hospital,Chinese Academy of Medical Sciences; Handan Central Hospital; Taian City Central Hospital; Tianjin People ' s Hospital; Guizhou Provincial People ' s Hospital; Central South University; Western Theater General Hospital; First Affiliated Hospital of Guangxi Medical University; Chengdu Jingdongfang Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 29, 2024 Category: Research Source Type: clinical trials
Music Therapy in Acute Leukemia Patients With Fatigue
Conditions: Acute Myeloid Leukemia; Fatigue Interventions: Other: Music Therapy Sponsors: Chang Gung University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 29, 2024 Category: Research Source Type: clinical trials
Phase I Study of HC-7366 With Azacitidine and Venetoclax for Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia Interventions: Drug: HC-7366; Drug: Azacitidine; Drug: Venetoclax Sponsors: M.D. Anderson Cancer Center; HiberCell, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 29, 2024 Category: Research Source Type: clinical trials
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
Conditions: Acute Myeloid Leukemia Interventions: Drug: Venetoclax; Drug: Revumenib Sponsors: M.D. Anderson Cancer Center; Syndax Pharmaceuticals; Break Through Cancer; AbbVie Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 29, 2024 Category: Research Source Type: clinical trials
An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia
Conditions: Acute Myeloid Leukemia, in Relapse; Acute Myeloid Leukemia Refractory Interventions: Genetic: CCTx-001 Sponsors: Advesya SAS Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials
